The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX-Reference-Cited by-同舟云学术

The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX

Published:2021-03 Issue:2 Volume:17 Page:227-237
ISSN:1479-6678
Container-title:Future Cardiology
language:en
Short-container-title:Future Cardiology

Author:

Gao Chao¹²^ORCID,Kogame Norihiro³,Modolo Rodrigo³⁴,Takahashi Kuniaki³,Wang Rutao¹²,Kawashima Hideyuki³,Ono Masafumi³,Hara Hironori³,Tomaniak Mariusz⁵,Zaman Azfar⁶,de Winter Robbert J³,van Geuns Robert-Jan²,Kaul Upendra⁷,Serruys Patrick W⁸⁹,Onuma Yoshinobu⁹

Affiliation:

1. Department of Cardiology, Xijing Hospital, Xi’an, China

2. Department of Cardiology, Radboud University, Nijmegen, The Netherlands

3. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

4. Department of Internal Medicine, Cardiology division, University of Campinas (UNICAMP), Campinas, SP, Brazil

5. Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands

6. Freeman Hospital, Newcastle University, & Newcastle upon Tyne Hospitals NHS Trust, Newcastle, NE7 7DN, UK

7. Academics & Research, Batra Hospital & Medical Research Center, New Delhi, India

8. NHLI, Imperial College London, London, SW3 6LY, UK

9. Department of Cardiology, National University of Ireland Galway, Galway, H91 TK33, Ireland

Abstract

Percutaneous coronary interventions with drug-eluting stents is currently the preferred revascularization treatment strategy for coronary artery disease. Following the first generation, the second-generation drug-eluting stents was designed with a thinner strut, better biocompatible polymer with/without bioresorbable coating or even polymer-free struts. The SUPRAFLEX stent system has ultra-thin struts (60 μm) across all stent diameters and a biodegradable polymer coating, enabling 70% of the sirolimus elution within 7 days. SUPRAFLEX has been assessed in large scale randomized controlled trials. This review summarizes the design of the SUPRAFLEX stent, the results of the pivotal clinical trials and outlines the ongoing research programs.

Publisher

Future Medicine Ltd

Subject

Cardiology and Cardiovascular Medicine,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fca-2019-0083

Reference36 articles.

1. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015

2. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

3. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

4. 2018 ESC/EACTS Guidelines on myocardial revascularization

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-Year Outcomes of Biodegradable Polymer-Coated Sirolimus-Eluting Coronary Stent in Acute Coronary Syndrome: A Patient-Level Pooled Analysis from Two Indian Registries;Cardiology;2024-05-07

2. Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years);Advances in Interventional Cardiology;2024

3. Ultra-thin everolimus-eluting stents in atherosclerotic lesions: Three years follow-up with subgroup analysis of ultra-long stents;Indian Heart Journal;2023-07

4. Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease–2;American Heart Journal;2023-02

5. Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial;EuroIntervention;2022-08